1. http://www.iasp-pain.org/Taxonomy
(accessed 8th May 2016).
2. National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173) December 2014.
https://www.nice.org.uk/guidance/cg173
(accessed 8th May 2016). NICE are the principle body responsible for offering evidence-based advice and guidance on a range of healthcare-related issues to the National Health Service (NHS) in England and Wales. Their guidance CG173 is a comprehensive review of treatments for neuropathic pain in adults using the very best quality evidence at that time.
3. Saxena AK, Azad R. Advances in the mechanisms, diagnosis and management of neuropathic pain: current opinions and future perspectives. Indian J Anaesth. 2006;50(4):249–57.
4. Dray A. Neuropathic pain: emerging treatments. Br J Anaesth. 2008;101(1):48–58.
5. Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic pain: a national clinical guideline (SIGN 136) December 2013.
http://sign.ac.uk/guidelines/fulltext/136
(accessed 8th May 2016). SIGN develops evidence-based clinical practice guidelines for the National Health Service (NHS) in Scotland. They are of high quality employing a rigorous systematic review of the scientific literature and are designed as a vehicle for accelerating the translation of new knowledge into action to meet their aim of reducing variations in practice and improving patient-important outcomes.